Advances in Myeloid Malignancies

Slides:

Advertisements

Similar presentations

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.

Advertisements

Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response New Findings in Hematology: Independent Conference.

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Soverini S et al. Proc ASH 2015;Abstract 346.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

Martinelli G et al. Proc ASH 2015;Abstract 679.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

New Psoriasis Treatments

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Improving Survival in Glioblastoma Multiforme

Targeting FLT3 Mutations in Acute Myeloid Leukemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Managing Inhibitors in Patients With Hemophilia A

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Progression After Cancer Immunotherapy in Advanced NSCLC

Monitoring Milestones in Patients With Chronic Myeloid Leukemia

New Standards of Care in ALK-Translocated Advanced NSCLC

Mutations and AML: Sampling, Assays, and Interpreting Results

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

PARP Inhibitors and Cancer: What Do You Need to Know?

Treating Transplant-Ineligible Patients With Multiple Myeloma

Chronic Myelogenous Leukemia Diagnosis and Treatment

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Addressing Disease Burden in Asthma

How Can we Improve Outcomes for the Elderly Patient with AML?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Targeting BTK Signaling in B-Cell Malignancies

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Mutational Testing to Select Novel Targeted Therapies in AML

Optimizing Frontline Care for Older Patients With Multiple Myeloma

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Advancing Care Across the Spectrum of Pancreatic Cancer

Future Directions in Myelofibrosis: Implications of Emerging Approaches.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Myeloid Updates From the Summer Congresses

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis

Advances in Immunotherapy for Peanut Allergy

Guide to Atopic Dermatitis

Chronic Myeloid Leukemia Challenge

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

FLT3 Inhibitors in AML.

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

Novel Concepts in the Management of RCC

The Psychiatrist's Role in Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

IDH Inhibitors in AML.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Risk Stratification in MDS

Program. Applying the Data and Practical Recommendations for Tailoring Treatment Selections for AML.

Presentation transcript:

Advances in Myeloid Malignancies

This program may include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Acute Myeloid Leukemia

Key Novel Agents for the Treatment of AML

Phase 1 Study of Vadastuximab Talirine (33A) in Older Pts With Treatment-Naive CD33-Positive AML

Phase 1 Study of Vadastuximab Talirine Plus Hypomethylating Agents in Older Patients With Treatment-Naive AML

Phase 1b Study of Vadastuximab Talirine Plus 7+3 Induction Therapy in Frontline AML

Phase 1 Study of Mutant IDH1 Inhibitor AG-120 in Pts With IDH1 Mutation-Positive Hematologic Malignancies

CHRYSALIS Phase 1/2 Study of Gilteritinib in Patients With R/R AML

Phase 1 Study of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Older Patients With AML

Phase 1 Dose-Escalation Study of MDM2 Inhibitor DS-3032b in Patients With Hematologic Malignancies

Phase 3 Trial of CPX-351 Vs 7 + 3 in Pts With Treatment-Naive Secondary AML: Subset Analyses

Summary of Key Investigational Agents in AML

Chronic Myeloid Leukemia

British DESTINY Study TKI Dose Reductions in Patients With Stable Molecular Responses

ENESTop Phase 2 Study Evaluating TFR in Patients With CP-CML Switching From Imatinib to Nilotinib

EURO-SKI Trial TKI Cessation in Patients With CML in Deep Molecular Response

CV Events in Patients Receiving TKIs

Effects of Comorbidities on TKI-Related QOL Changes in Patients With CP-CML

Phase 1 Study of BCR-ABL Inhibitor ABL001 in Patients With CP-CML and Prior TKI Failure

Phase 1 Study of Ruxolitinib Plus Nilotinib in Patients With CP-CML and Molecular Evidence of Disease

Conclusions: Recent Advances in CML

Myeloproliferative Neoplasms

PERSIST-2 -- Phase 3 Trial of Pacritinib Vs Best Available Therapy (Including Ruxolitinib) in Patients With MF and Thrombocytopenia Study Design

PERSIST-2 Results

PROUD-PV Phase 3 Trial of AOP2014 Vs HU in Patients With PV

MPD-RC 112 Phase 3 Trial of Frontline PegIFN Alfa 2a Vs HU in Patients With High-Risk PV and ET

Living With MPN Patient Survey Effects on Employment

International MPN LANDMARK Survey Effects of MPNs on QOL and Productivity

Myelodysplastic Syndrome

Phase 1 Study of Mutant IDH2 Inhibitor Enasidenib In Patients With MDS

PACE-MDS Phase 2 Study of Luspatercept in Patients With Low-Intermediate-Risk MDS

MDS Clinical Research Consortium Phase 2 Study of Low-Dose DEC Vs AZA in Patients With Low- or Intermediate-1-Risk MDS

E2905 Phase 3 Trial of Len Plus EA in Epo-Refractory Lower-Risk Non-Del(5q) MDS

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)